Surrozen, Inc./DE (SRZN) stock
SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$31.61−0.06 (-0.19%)
Close on Nov 13, 2026Market cap $371.53MP/E –Yield –
Surrozen operating margin
Operating margin is operating income as a percentage of revenue.
Surrozen's operating margin for the twelve months ending Jun 30, 2026 was -385.3%. For fiscal 2025 it was -1210.6%, against -239.7% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1210.6% | −970.9 |
| FY2024 | Dec 31, 2024 | -239.7% | +115.0 |
| FY2022 | Dec 31, 2022 | -354.7% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -207.4% | +709.9 |
| Q1 FY2026 | Mar 31, 2026 | -209.1% | +762.5 |
| Q4 FY2025 | Dec 31, 2025 | -2393.8% | −1082.0 |
| Q3 FY2025 | Sep 30, 2025 | -1107.3% | −1119.6 |
| Q2 FY2025 | Jun 30, 2025 | -917.3% | – |
| Q1 FY2025 | Mar 31, 2025 | -971.6% | – |
| Q4 FY2024 | Dec 31, 2024 | -1311.8% | – |
| Q3 FY2024 | Sep 30, 2024 | 12.3% | – |
See a number that looks wrong?